Drug-drug interactions are a common health problem. They cause more serious side effects and are more common in patients with multiple diseases, especially in the elderly. It was aimed herein to examine the frequency of drug -drug interactions in elderly patients treated in the intensive care unit due to urological diseases. This retrospective study was performed on hospital ized patients over the age of 85 years who had urologic diseases and were treated in the intensive care unit. Drug-drug interactions were evaluated using the Rx mediapharma and Lexi interact programs. A total of 91 different medications were administered to 100 patients. Of the patients, 87 had drug-drug interactions and the total number of drug-drug interactions was 550. When all of the interactions were examined, it was observed that drug - drug interactions were most often to cause side effects on the cardiovascular system, such as arrhythmia, hypotension, or hypertension (40%). The drugs that were most involved in drug-drug interactions were furosemide (n: 87), enoxaparin sodium (n: 74), and acetyl salicylic acid (n: 45). The results of the study showed that drug-drug interactions were seen quite frequently in elderly patients hospitalized due to primary urological diseases in the intensive care unit. The most common adverse drug reactions in these patients were bleeding, changes in the therapeutic levels of drugs, and hyperkalemia.
___
1. Re MD, Fogli S, Derosa L, et alThe role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide. Cancer Treatment Rev 2017; 55: 71-82.
2. Daniel Keizman, Peng Huang, Michael A Carducci, Mario A Eisenberger. Contemporary experience with ketoconazole in patients with metastatic castration-resistant prostate cancer: clinical factors associated with PSA response and disease progression. J Urol 2012; 72: 461- 467.
3. Vasaitis TS, Bruno RD, Njar VC. CYP17 inhibitors for prostate cancer therapy. J Steroid Biochem Mol Biol 2011; 125: 23-31.
4. Spriet I, Meersseman W, De Hoon J, et al. Mini-series: II. clinical aspects. clinically relevant CYP450-mediated drug interactions in the ICU. Intensive care med 2009; 35: 603- 612.
5. Oksuz E, Bugday MS, Soyalp C, et al. Drugdrug interactions in intensive care units and potential clinical consequences of these interactions. Ann Med Res 2019; 26: 2158- 2163.
6. Davies EA, O’Mahony MS. Adverse drug reactions in special populations – the elderly. Br J Clin Pharmacol 2015; 80: 796-807.
7. Gnjidic D, Johnell K. Clinical implications from drug–drug and drug–disease interactions in older people. Clin Exp Pharmacol Physiol 2013; 40: 320-325.
8. Lin CF, Wang CY. Polypharmacy, Aging and Potential Drug-Drug Interactions in Outpatients in Taiwan. Drugs Aging 2011; 28: 220-225.
9. Assefa YA, Kedir A, Kahaliw W. Survey on Polypharmacy and Drug-Drug Interactions Among Elderly People with Cardiovascular Diseases at Yekatit 12 Hospital, Addis Ababa, Ethiopia. Integr Pharm Res Pract 2020; 9: 1-9.
10. Hebenstreit D, Pichler R, Heidegger I. Drug- Drug Interactions in Prostate Cancer Treatment. Clin Genitourin Cancer 2019; 18: 71-82.
11. Hines LE, Murphy JE, et al. Potentially Harmful Drug–Drug Interactions in the Elderly: A Review. Am J Geriatr Pharmac 2011; 9; 364-377.
12. Lenssen R, Heidenreich A, Schulz JB, et al. Analysis of drug-related problems in three departments of a German University hospital. Int J Clin Pharm 2016; 38: 119-126.